1
|
Zhang X, Tan Y, Li T, Tan D, Fu B, Yang M, Chen Y, Cao M, Xuan C, Du Q, Hu R, Wang Q. Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane. Drug Resist Updat 2024; 76:101112. [PMID: 38924997 DOI: 10.1016/j.drup.2024.101112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 05/31/2024] [Accepted: 06/14/2024] [Indexed: 06/28/2024]
Abstract
AIMS Despite aggressive treatment, the recurrence of glioma is an inevitable occurrence, leading to unsatisfactory clinical outcomes. A plausible explanation for this phenomenon is the phenotypic alterations that glioma cells undergo aggressive therapies, such as TMZ-therapy. However, the underlying mechanisms behind these changes are not well understood. METHODS The TMZ chemotherapy resistance model was employed to assess the expression of intercellular adhesion molecule-1 (ICAM1) in both in vitro and in vivo settings. The potential role of ICAM1 in regulating TMZ chemotherapy resistance was investigated through knockout and overexpression techniques. Furthermore, the mechanism underlying ICAM1-mediated TMZ chemotherapy resistance was examined using diverse molecular biological methods, and the lipid raft protein was subsequently isolated to investigate the cellular subcomponents where ICAM1 operates. RESULTS Acquired TMZ resistant (TMZ-R) glioma models heightened production of intercellular adhesion molecule-1 (ICAM1) in TMZ-R glioma cells. Additionally, we observed a significant suppression of TMZ-R glioma proliferation upon inhibition of ICAM1, which was attributed to the enhanced intracellular accumulation of TMZ. Our findings provide evidence supporting the role of ICAM1, a proinflammatory marker, in promoting the expression of ABCB1 on the cell membrane of TMZ-resistant cells. We have elucidated the mechanistic pathway by which ICAM1 modulates phosphorylated moesin, leading to an increase in ABCB1 expression on the membrane. Furthermore, our research has revealed that the regulation of moesin by ICAM1 was instrumental in facilitating the assembly of ABCB1 exclusively on the lipid raft of the membrane. CONCLUSIONS Our findings suggest that ICAM1 is an important mediator in TMZ-resistant gliomas and targeting ICAM1 may provide a new strategy for enhancing the efficacy of TMZ therapy against glioma.
Collapse
Affiliation(s)
- Xin Zhang
- School of Pharmacy, Anhui Medical University, Hefei, Anhui, PR China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, PR China; State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Yingying Tan
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Tao Li
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Dashan Tan
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Bin Fu
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Mengdi Yang
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Yaxin Chen
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Mengran Cao
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Chenyuan Xuan
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Qianming Du
- General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, PR China
| | - Rong Hu
- State Key Laboratory of Natural Medicines, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, PR China.
| | - Qing Wang
- Department of Neurosurgery, Jiangnan University Medical Center, Wuxi, Jiangsu, PR China.
| |
Collapse
|
2
|
Qu X, Liu B, Wang L, Liu L, Zhao W, Liu C, Ding J, Zhao S, Xu B, Yu H, Zhang X, Chai J. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer. Drug Resist Updat 2023; 68:100936. [PMID: 36764075 DOI: 10.1016/j.drup.2023.100936] [Citation(s) in RCA: 48] [Impact Index Per Article: 48.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 01/09/2023] [Accepted: 01/20/2023] [Indexed: 02/01/2023]
Abstract
AIMS Long non-coding RNAs (lncRNAs), as one of the components of exosomes derived from cancer-associated fibroblasts (CAFs), exhibit a crucial role in the pathogenesis and chemoresistance of gastric cancer (GC). Herein, we investigated the role and mechanism of a novel lncRNA disheveled binding antagonist of beta catenin3 antisense1 (DACT3-AS1) and its involvement in GC. METHODS DACT3-AS1 was identified by RNA-sequencing and verified by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The functional role of DACT3-AS1 in GC was evaluated using in vitro and in vivo experiments including Transwell assay, 5-Ethynyl-2'-deoxyuridine (EdU) assay, immunoblotting, and xenograft tumor mouse model. Dual-luciferase reporter assay was performed to assess the association between genes. RESULTS DACT3-AS1 was downregulated and involved in poor prognosis of patients with GC. The results from both in vitro and in vivo experiments showed that DACT3-AS1 suppressed cell proliferation, migration, and invasion through targeting miR-181a-5p/sirtuin 1 (SIRT1) axis. Additionally, DACT3-AS1 was transmitted from CAFs to GC cells mainly via exosomes. Exosomal DACT3-AS1 alleviated xenograft tumor growth. DACT3-AS1 conferred sensitivity of cancer cells to oxaliplatin through SIRT1-mediated ferroptosis both in vitro and in vivo. CONCLUSIONS CAFs-derived exosomal DACT3-AS1 is a suppressive regulator in malignant transformation and oxaliplatin resistance. DACT3-AS1 could be used for diagnosis and treatment of GC.
Collapse
Affiliation(s)
- Xianlin Qu
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Bing Liu
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Longgang Wang
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Luguang Liu
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Weizhu Zhao
- Department of Radiology, Shandong University, Shandong Cancer Hospital and Institute, Jinan, Shandong, China; Department of Oncology, Binzhou People's Hospital Affiliated to Shandong First Medical University, Binzhou, Shandong, China
| | - Changlei Liu
- Department of scientific research project, Shandong Excalibur Medical Research. LTD, Jinan, Shandong, China
| | - Jishuang Ding
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Siwei Zhao
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Botao Xu
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Hang Yu
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China
| | - Xiang Zhang
- Department of scientific research project, Shandong Excalibur Medical Research. LTD, Jinan, Shandong, China
| | - Jie Chai
- Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China.
| |
Collapse
|
3
|
Zhang X, Liu W, Edaki K, Nakazawa Y, Takahashi S, Sunakawa H, Mizoi K, Ogihara T. Slug Mediates MRP2 Expression in Non-Small Cell Lung Cancer Cells. Biomolecules 2022; 12:biom12060806. [PMID: 35740931 PMCID: PMC9220960 DOI: 10.3390/biom12060806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 06/03/2022] [Accepted: 06/06/2022] [Indexed: 02/01/2023] Open
Abstract
Transcriptional factors, such as Snail, Slug, and Smuc, that cause epithelial-mesenchymal transition are thought to regulate the expression of Ezrin, Radixin, and Moesin (ERM proteins), which serve as anchors for efflux transporters on the plasma membrane surface. Our previous results using lung cancer clinical samples indicated a correlation between Slug and efflux transporter MRP2. In the current study, we aimed to evaluate the relationships between MRP2, ERM proteins, and Slug in lung cancer cells. HCC827 cells were transfected by Mock and Slug plasmid. Both mRNA expression levels and protein expression levels were measured. Then, the activity of MRP2 was evaluated using CDCF and SN-38 (MRP2 substrates). HCC827 cells transfected with the Slug plasmid showed significantly higher mRNA expression levels of MRP2 than the Mock-transfected cells. However, the mRNA expression levels of ERM proteins did not show a significant difference between Slug-transfected cells and Mock-transfected cells. Protein expression of MRP2 was increased in Slug-transfected cells. The uptake of both CDCF and SN-38 was significantly decreased after transfection with Slug. This change was abrogated by treatment with MK571, an MRP2 inhibitor. The viability of Slug-transfected cells, compared to Mock cells, significantly increased after incubation with SN-38. Thus, Slug may increase the mRNA and protein expression of MRP2 without regulation by ERM proteins in HCC827 cells, thereby enhancing MRP2 activity. Inhibition of Slug may reduce the efficacy of multidrug resistance in lung cancer.
Collapse
Affiliation(s)
- Xieyi Zhang
- Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-chou, Takasaki-shi 370-0033, Gunma, Japan; (K.E.); (Y.N.); (S.T.); (K.M.); (T.O.)
- Correspondence: ; Tel.: +81-273521180; Fax: +81-273521118
| | - Wangyang Liu
- Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki-shi 370-0033, Gunma, Japan; (W.L.); (H.S.)
| | - Kazue Edaki
- Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-chou, Takasaki-shi 370-0033, Gunma, Japan; (K.E.); (Y.N.); (S.T.); (K.M.); (T.O.)
| | - Yuta Nakazawa
- Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-chou, Takasaki-shi 370-0033, Gunma, Japan; (K.E.); (Y.N.); (S.T.); (K.M.); (T.O.)
| | - Saori Takahashi
- Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-chou, Takasaki-shi 370-0033, Gunma, Japan; (K.E.); (Y.N.); (S.T.); (K.M.); (T.O.)
| | - Hiroki Sunakawa
- Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki-shi 370-0033, Gunma, Japan; (W.L.); (H.S.)
| | - Kenta Mizoi
- Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-chou, Takasaki-shi 370-0033, Gunma, Japan; (K.E.); (Y.N.); (S.T.); (K.M.); (T.O.)
| | - Takuo Ogihara
- Laboratory of Biopharmaceutics, Department of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-chou, Takasaki-shi 370-0033, Gunma, Japan; (K.E.); (Y.N.); (S.T.); (K.M.); (T.O.)
- Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki-shi 370-0033, Gunma, Japan; (W.L.); (H.S.)
| |
Collapse
|